ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.145,54
0,43%
S&P 500
5.487,03
0,00%
Dow Jones
38.834,86
0,00%
Euro vs US Dollar
1,07292
-0,17%
Bitcoin
65.970,65
1,54%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. PMV Pharmaceuticals Inc (PMVP)

  7. PMV Pharmaceuticals Inc (PMVP) News

PMVP

PMV Pharmaceuticals (PMVP)

PMV Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PMVP
DatumZeitQuelleÜberschriftSymbolFirma
10/06/202422h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
07/06/202414h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
30/05/202413h00GlobeNewswire Inc.PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in JuneNASDAQ:PMVPPMV Pharmaceuticals Inc
29/05/202413h00Business WireFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorNASDAQ:PMVPPMV Pharmaceuticals Inc
29/05/202413h00GlobeNewswire Inc.Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorNASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202414h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202414h00GlobeNewswire Inc.PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
27/03/202413h00GlobeNewswire Inc.PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsNASDAQ:PMVPPMV Pharmaceuticals Inc
18/03/202421h01GlobeNewswire Inc.PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s CancerNASDAQ:PMVPPMV Pharmaceuticals Inc
29/02/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
29/02/202422h01GlobeNewswire Inc.PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
26/02/202414h00GlobeNewswire Inc.PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:PMVPPMV Pharmaceuticals Inc
24/01/202415h01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PMVPPMV Pharmaceuticals Inc
22/01/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
22/01/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
18/01/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
18/01/202422h01GlobeNewswire Inc.PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayNASDAQ:PMVPPMV Pharmaceuticals Inc
11/01/202422h18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
05/01/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
05/01/202422h01GlobeNewswire Inc.PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage DevelopmentNASDAQ:PMVPPMV Pharmaceuticals Inc
09/11/202314h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PMVPPMV Pharmaceuticals Inc
09/11/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
09/11/202314h00GlobeNewswire Inc.PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
12/10/202323h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
12/10/202318h30GlobeNewswire Inc.PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C MutationNASDAQ:PMVPPMV Pharmaceuticals Inc
11/10/202322h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
11/10/202318h00GlobeNewswire Inc.PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL WebinarNASDAQ:PMVPPMV Pharmaceuticals Inc
20/09/202322h05GlobeNewswire Inc.PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:PMVPPMV Pharmaceuticals Inc
18/09/202322h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PMVP

Kürzlich von Ihnen besucht

NASDAQ
FSVEX
Fidelity Advisor Sustain...
USOTC
MDVLQ
MedAvail (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten